- Home
- DHIL vs ZURA Comparison
DHIL vs ZURA Comparison
Compare DHIL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHIL | ZURA |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.2M | 252.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DHIL | ZURA |
|---|---|---|
| Price | $169.50 | $5.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 48.3K | ★ 549.2K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.21 | N/A |
| Revenue | ★ $149,665,296.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.85 | ★ N/A |
| Revenue Growth | ★ 2.65 | N/A |
| 52 Week Low | $114.11 | $0.97 |
| 52 Week High | $171.43 | $5.62 |
Technical Indicators
Market Signals| Indicator | DHIL | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 79.28 | 76.60 |
| Support Level | $169.20 | $4.00 |
| Resistance Level | $170.53 | $5.62 |
| Average True Range (ATR) | 1.21 | 0.35 |
| MACD | 0.64 | 0.12 |
| Stochastic Oscillator | 38.54 | 80.67 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.